Literature DB >> 1977519

Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes.

A Lichtenstein1, J Berenson, J F Gera, K Waldburger, O Martinez-Maza, J S Berek.   

Abstract

Since overexpression of HER2/neu oncogenes in breast cancer cells is associated with resistance to the cytotoxic effect of tumor necrosis factor (TNF), we investigated whether this correlation also existed for ovarian cancer targets. Nine continuously cultured human ovarian cancer lines were studied and compared to 3 breast cancer lines. Three of the ovarian and 1 breast cancer line demonstrated amplified HER2/neu genes by Southern analysis, increased HER2/neu RNA by Northern analysis, and marked immunoperoxidase staining for HER2/neu protein. The other 8 lines contained unamplified genes and undetectable RNA and protein. All 4 overexpressed lines were relatively resistant to the cytotoxic effects of TNF. Interestingly, they were also resistant to lymphokine-activated killer cells. In contrast, 7 of 8 nonexpressed lines showed sensitivity to TNF and all 8 were sensitive to lymphokine-activated killer cells. There was no difference in sensitivity to lysis by hydrogen peroxide or peptide defensins between over- and nonexpressed lines. These data indicate that expression of HER2/neu oncogenes may impart a proliferative advantage in tumor cells due to induction of resistance to several different cytotoxic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1977519

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Defensins: microbicidal and cytotoxic peptides of mammalian host defense cells.

Authors:  T Ganz; A Oren; R I Lehrer
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

Review 2.  The role of cytokines in pancreatic cancer.

Authors:  J Schmielau; H Kalthoff; C Roeder; W Schmiegel
Journal:  Int J Pancreatol       Date:  1996-06

Review 3.  Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.

Authors:  H M Shepard; G D Lewis; J C Sarup; B M Fendly; D Maneval; J Mordenti; I Figari; C E Kotts; M A Palladino; A Ullrich
Journal:  J Clin Immunol       Date:  1991-05       Impact factor: 8.317

4.  A polymerase chain reaction-based microsatellite typing assay used for tumor cell line identification.

Authors:  B L King; A Lichtenstein; J Berenson; B M Kacinski
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

5.  Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.

Authors:  G D Lewis; I Figari; B Fendly; W L Wong; P Carter; C Gorman; H M Shepard
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

6.  Interferon-gamma-induced increased sensitivity of HER2/neu-overexpressing tumor cells to lymphokine-activated killer cell lysis: importance of ICAM-1 in binding and post-binding events.

Authors:  C Fady; A Gardner; J F Gera; A Lichtenstein
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

7.  Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha.

Authors:  H Kalthoff; C Roeder; J Gieseking; I Humburg; W Schmiegel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

8.  Resistance of HER2/neu-overexpressing tumor targets to lymphokine-activated-killer-cell-mediated lysis: evidence for deficiency of binding and post-binding events.

Authors:  C Fady; A Gardner; J F Gera; A Lichtenstein
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

9.  In vivo tumorigenicity and in vitro sensitivity to tumor-necrosis-factor alpha mediated killing of c-Ha-ras-transformed cells.

Authors:  B Gonen; O Kahana; I P Witz
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

10.  Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells.

Authors:  N I Obiri; J P Siegel; F Varricchio; R K Puri
Journal:  Clin Exp Immunol       Date:  1994-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.